TransMedics Group (TMDX)
(Delayed Data from NSDQ)
$92.08 USD
+2.83 (3.17%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $92.08 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
D Value B Growth C Momentum C VGM
Price, Consensus and EPS Surprise
TMDX 92.08 +2.83(3.17%)
Will TMDX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for TMDX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TMDX
Edwards Lifesciences (EW) Q1 Earnings Top, 2024 Sales View Up
Should Lifeward (LFWD) be in Your Portfolio Ahead of Q1 Earnings?
TMDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Exploring Analyst Estimates for TransMedics (TMDX) Q1 Earnings, Beyond Revenue and EPS
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
Other News for TMDX
What's Driving Tandem Diabetes Care Inc's Surprising 31% Stock Rally?
TransMedics Group: Founder Led Company With Solid Potential
TransMedics to Report First Quarter 2024 Financial Results on April 30, 2024
3 Must-Own Stocks for Sustained Growth Over the Next 18 Months
Wall Street Favorites: 3 Long-Term Stocks With Strong Buy Ratings for April 2024